What is the best peptide for weight loss?

Based on current clinical evidence, tirzepatide (Mounjaro®) has demonstrated the greatest weight loss in clinical trials — up to 22.5% body weight reduction at the highest dose in the SURMOUNT-1 trial. However, 'best' depends on individual circumstances, availability, and medical history. Semaglutide (Wegovy®) is the most established option with NICE approval for weight management in the UK. Your GP or weight management specialist can advise on the most appropriate option based on your individual needs, comorbidities, and eligibility criteria.

Can I get weight loss peptides on the NHS?

Yes, certain GLP-1 agonists are available on the NHS for weight management. Semaglutide (Wegovy®) and liraglutide (Saxenda®) are NICE-approved for adults with BMI ≥35 (or ≥30 with at least one weight-related comorbidity) as part of a specialist weight management service. However, access varies by region and is subject to local commissioning decisions, specialist referral, and supply availability. Your GP can refer you to a specialist weight management service to assess eligibility. Private prescriptions are also available through CQC-regulated clinics.

How much weight can I lose with peptides?

Clinical trial data show the following average weight loss over approximately 68 weeks of treatment: semaglutide 2.4mg (Wegovy®) approximately 15% of body weight; tirzepatide at maximum dose approximately 22.5%; liraglutide 3mg (Saxenda®) approximately 8%. Individual results vary considerably based on adherence, diet, exercise, and baseline characteristics. It is important to note that weight regain commonly occurs after discontinuation, highlighting the chronic nature of obesity and the potential need for long-term treatment.

Are weight loss peptides safe?

Approved GLP-1 agonists (semaglutide, tirzepatide, liraglutide) have undergone rigorous clinical trials and regulatory review by the MHRA and other authorities. They have well-characterised safety profiles, with gastrointestinal side effects being most common. Serious but rare risks include pancreatitis and gallbladder events. They are generally considered safe when prescribed appropriately and used under medical supervision. However, unregulated peptides purchased online may be unsafe — the MHRA has issued specific warnings about counterfeit and contaminated products.

What is the difference between Ozempic and Wegovy?

Ozempic® and Wegovy® both contain semaglutide and are manufactured by Novo Nordisk. The key differences are: Ozempic® is licensed for type 2 diabetes at doses up to 1mg (or 2mg) weekly; Wegovy® is licensed specifically for weight management at a higher dose of 2.4mg weekly. While Ozempic® produces weight loss as a secondary benefit, prescribing it 'off-label' purely for weight management is not recommended by NICE. Wegovy® underwent separate clinical trials (STEP programme) specifically evaluating weight management outcomes.

Do I need a prescription for weight loss peptides in the UK?

Yes. All approved GLP-1 agonists for weight management (Wegovy®, Saxenda®, Mounjaro®) are prescription-only medicines (POMs) in the UK, regulated by the MHRA. They must be prescribed by a qualified healthcare professional following appropriate medical assessment. Selling these medicines without a prescription is an offence, and products from unregulated online sellers may be counterfeit or contaminated, so buying them that way is unsafe and strongly discouraged. Legitimate prescriptions can be obtained through NHS weight management services or CQC-registered private clinics.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 25 September 2026

Symptom Guide

Part of: Metabolic and Weight

Peptides for Weight Loss

Last updated: 2026-09-25

Weight loss has become one of the most significant public health priorities in the United Kingdom. According to NHS England data, approximately two-thirds of adults in England are living with overweight or obesity, contributing to an estimated £6.5 billion annual cost to the NHS. The arrival of GLP-1 receptor agonist peptides has been described as a paradigm shift in obesity medicine — offering clinically meaningful weight reduction for the first time through pharmacological intervention.

The distinction between "weight loss" and "fat loss" is worth noting: weight loss encompasses total body mass reduction (including fat, water, and potentially lean tissue), whereas fat loss specifically targets adipose tissue. This guide takes the broader, clinically relevant perspective of weight loss as a whole, reflecting how these treatments are discussed in NHS and NICE guidelines.

NICE has approved several GLP-1-based therapies for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The MHRA regulates these products in the UK, and legitimate prescriptions are available through NHS obesity services, specialist weight management clinics, and regulated private prescribers.

Important Disclaimer: This page provides educational information about peptides researched for weight loss. It is not medical advice. Weight management should be discussed with a qualified healthcare professional. Prescription peptide medications for weight loss are regulated by the MHRA and require appropriate medical supervision. Never purchase or self-administer unregulated peptide products.

What this guide is — and what to do first

Peptide research for this condition is interesting, but it is not the first thing to consider. The blocks below cover standard UK care, when to see your GP, what licensed treatments exist, and how the peptide evidence actually stacks up.

Standard care first

Sustained weight loss requires a structured plan: calorie deficit (500-750 kcal/day below maintenance), increased protein (1.2-1.6 g/kg) to preserve lean mass, resistance training 2-3x/week, aerobic activity, sleep, stress management. NHS Tier 2 (12-week behavioural support, BMI ≥30 or ≥27.5 with comorbidities) and NHS Tier 3 (multidisciplinary, BMI ≥35 with comorbidities) services are GP-referral routes. Bariatric assessment for BMI ≥40 (or ≥35 with comorbidities). Licensed pharmacotherapy where appropriate.

When to speak to your GP

See your GP if BMI ≥30 (or ≥27.5 for South Asian / Chinese / Black African-Caribbean ethnic groups) and you want a structured plan; if you have weight-related comorbidities; if you are considering any pharmacological treatment. Do not start a GLP-1 from an online seller without a UK prescription — counterfeit pens are a documented MHRA issue.

UK-approved treatments for this condition

Licensed UK weight-management GLP-1s: Wegovy (NICE TA875), Mounjaro (NICE TA1026), Saxenda. All POMs; access via NHS Tier 3 or GMC-registered private prescriber. Orlistat (Xenical / Alli) — lipase inhibitor. Bariatric surgery — NHS-funded for eligible patients (sleeve gastrectomy, Roux-en-Y bypass).

What the peptide evidence actually says

Peptide	Human evidence	UK status	Honest verdict
Semaglutide (Wegovy)	Strong (STEP trials)	Licensed POM	MHRA-licensed. ~15% mean weight loss at 68 weeks. NHS via TA875.
Tirzepatide (Mounjaro)	Strong (SURMOUNT trials)	Licensed POM	MHRA-licensed. ~22% mean weight loss at 72 weeks. NHS via TA1026 (phased rollout).
Liraglutide (Saxenda)	Strong (SCALE trials)	Licensed POM	Daily injection; ~5-8% weight loss; older GLP-1.
Retatrutide	Phase 2 only	Investigational	NOT licensed; trial-only lawful access.
AOD-9604 / HGH Fragment	Failed Phase 3 / none	Unlicensed	Not validated for cosmetic fat loss.
Tesofensine	Phase 2 only; cardiovascular signal	Unlicensed	Development stalled on safety. Not a peptide.

How Peptides May Help

Peptides may support weight loss through several interconnected mechanisms:

1. Appetite Suppression via GLP-1 Receptor Agonism Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally released from the gut after eating. GLP-1 receptor agonists such as semaglutide and liraglutide mimic this hormone at supraphysiological levels, activating receptors in the hypothalamus and brainstem that regulate hunger and satiety. This produces a profound reduction in appetite, with patients typically reporting significantly diminished food cravings and earlier satisfaction during meals.

2. Gastric Emptying Delay GLP-1 receptor agonists slow the rate at which food passes from the stomach into the small intestine (gastroparesis effect). This prolonged gastric retention contributes to sustained feelings of fullness after smaller meals, reduces postprandial glucose spikes, and naturally decreases total caloric intake throughout the day. The effect is dose-dependent and a significant contributor to weight reduction.

3. Central Satiety Signalling Beyond peripheral gut signalling, GLP-1 agonists cross the blood-brain barrier and act directly on appetite-regulating centres in the central nervous system. Research has demonstrated effects on the hypothalamic arcuate nucleus, the mesolimbic reward system, and areas involved in food-related decision-making. This central action reduces the hedonic drive to eat — the desire for food beyond physiological need — which is a key driver of overconsumption.

4. Metabolic Rate Enhancement Certain peptide approaches may influence basal metabolic rate and energy expenditure. Dual agonists such as tirzepatide (GLP-1/GIP) and triple agonists like retatrutide (GLP-1/GIP/glucagon) have demonstrated effects on energy expenditure through glucagon receptor activation, which promotes hepatic fatty acid oxidation and thermogenesis. This addresses the metabolic adaptation that typically occurs during caloric restriction, potentially reducing the "metabolic slowdown" associated with weight loss.

5. Adipocyte Regulation Some peptides under investigation may influence adipose tissue biology directly. Research into growth hormone fragments such as AOD-9604 has explored effects on lipolysis (fat breakdown) and lipogenesis (fat storage) at the adipocyte level. Dual and triple agonists also appear to influence adipose tissue distribution, potentially favouring reduction of metabolically harmful visceral fat over subcutaneous fat deposits. This may improve metabolic health markers beyond what would be expected from weight loss alone.

Researched Peptides

Semaglutide

The most widely prescribed GLP-1 agonist for weight management globally

Available in the UK as Wegovy® (subcutaneous, 2.4mg weekly) for weight management and as Ozempic® (1mg weekly) for type 2 diabetes. NICE-approved for weight management in adults with BMI ≥35 (or ≥30 with comorbidities) through specialist weight management services. The STEP trial programme demonstrated average weight loss of approximately 15% of body weight over 68 weeks. NHS availability is expanding but subject to supply and commissioning arrangements.

Tirzepatide

Dual GLP-1/GIP receptor agonist with superior weight loss efficacy in trials

Available in the UK as Mounjaro® for type 2 diabetes (NICE-approved 2024). Weight management indication (Zepbound®) is anticipated for UK approval. The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction at the highest dose — the greatest weight loss achieved by any single peptide agent in clinical trials. Dual incretin agonism provides complementary metabolic benefits beyond GLP-1 alone.

Liraglutide

First-generation daily GLP-1 agonist approved for weight management

Available as Saxenda® (3mg daily injection) for weight management in the UK. NICE-approved for adults with BMI ≥35 (or ≥30 with comorbidities) for up to 2 years. Requires daily injection (vs weekly for semaglutide). The SCALE trial showed approximately 8% body weight loss. Largely superseded by semaglutide in clinical preference but remains an option where semaglutide is unsuitable or unavailable.

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist in late-stage clinical trials

Phase 3 trials are underway following remarkable Phase 2 results showing up to 24% body weight reduction over 48 weeks. The addition of glucagon receptor agonism to dual incretin activity may enhance energy expenditure and hepatic fat reduction. Not yet approved in any jurisdiction. Represents the next frontier in peptide-based weight management, with potential UK availability dependent on trial outcomes and MHRA review.

Survodutide

Dual GLP-1/glucagon receptor agonist with metabolic benefits

In Phase 3 clinical development for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Phase 2 data demonstrated approximately 19% weight loss alongside significant reductions in liver fat. The glucagon component may provide metabolic advantages including enhanced energy expenditure. Not yet approved; UK availability dependent on successful trials and MHRA approval.

Cagrilintide

Long-acting amylin analogue being developed in combination with semaglutide

Being studied in combination with semaglutide (CagriSema) for enhanced weight loss beyond semaglutide alone. Amylin is a pancreatic peptide that promotes satiety and slows gastric emptying through mechanisms complementary to GLP-1. Phase 3 REDEFINE trial programme is ongoing. The combination aims to address the efficacy plateau seen with GLP-1 monotherapy. Not yet approved.

AOD-9604

Modified growth hormone fragment researched for fat metabolism

A modified fragment of human growth hormone (amino acids 177–191) researched for its effects on fat metabolism without the broader hormonal effects of full-length GH. Early research suggested lipolytic properties, but clinical trial data have been disappointing and it has not achieved regulatory approval for weight loss. Not available on the NHS. Classified as a research peptide with limited clinical evidence supporting efficacy.

Tesofensine

Triple monoamine reuptake inhibitor with central appetite suppression

Originally developed as a neurological drug, tesofensine inhibits reuptake of noradrenaline, dopamine, and serotonin, producing significant appetite suppression and modest increases in metabolic rate. In the Phase 2 TIPO-1 trial, mean weight loss exceeded diet plus placebo by up to 10.6% at the highest (1.0 mg) dose over 24 weeks. Development has been limited by cardiovascular safety concerns (increased heart rate and blood pressure). Not approved in the UK or any major market. Included for completeness but not a peptide in the traditional sense.

Peptide Comparisons

Wegovy® (Semaglutide) vs Mounjaro® (Tirzepatide) — The Two Main UK Options:

Semaglutide (Wegovy®) and tirzepatide (Mounjaro®) represent the two leading peptide-based weight management options in or approaching the UK market. In head-to-head trials (SURMOUNT vs STEP), tirzepatide has demonstrated superior weight loss at maximum doses (up to 22.5% vs approximately 15% body weight). However, several practical differences matter for UK patients:

- Current UK Availability: Wegovy® has NICE approval for weight management; Mounjaro® is currently NICE-approved for type 2 diabetes only, with weight management approval anticipated - Mechanism: Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist — the additional GIP agonism may contribute to enhanced efficacy and metabolic benefits - Administration: Both are once-weekly subcutaneous injections with similar titration schedules - Side Effects: Both share GI side effects (nausea, vomiting, diarrhoea), though tirzepatide may have a slightly more favourable GI tolerability profile in some studies - Cost & Access: NHS access is subject to commissioning arrangements, specialist referral pathways, and ongoing supply considerations

For a detailed comparison, see our Semaglutide vs Tirzepatide comparison guide

Safety Considerations

Important Safety Considerations for Weight Loss Peptides:

Common GLP-1 Agonist Side Effects: - Gastrointestinal effects are the most frequently reported: nausea (particularly during dose titration), vomiting, diarrhoea, constipation, and abdominal discomfort. These typically diminish over time and are managed through gradual dose escalation - Injection site reactions (redness, swelling, itching) occur in a minority of patients

Serious Safety Concerns: - Pancreatitis Risk: All GLP-1 agonists carry a precautionary warning regarding pancreatitis. Patients should be counselled to report severe, persistent abdominal pain. Those with a history of pancreatitis should generally avoid GLP-1 therapies - Gallbladder Events: Rapid weight loss from any cause increases the risk of cholelithiasis (gallstones). GLP-1 agonists may carry an additional gallbladder-related risk - Thyroid Concerns: GLP-1 agonists carry a boxed warning (in the US) regarding medullary thyroid carcinoma risk based on rodent studies. The clinical relevance in humans remains uncertain, but they are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome - Muscle Mass Loss: Significant weight loss with GLP-1 agonists includes lean mass loss (approximately 25-40% of total weight lost may be lean tissue). Resistance exercise and adequate protein intake are strongly recommended to mitigate this effect

Contraindications: - Personal or family history of medullary thyroid carcinoma or MEN2 - History of pancreatitis (relative contraindication) - Pregnancy and breastfeeding - Severe gastrointestinal disease (e.g., gastroparesis) - Caution in patients with renal impairment (dose adjustment may be required)

WADA Status: - GLP-1 receptor agonists are not currently on the World Anti-Doping Agency (WADA) Prohibited List. However, athletes should be aware that this status could change and should consult their sport's anti-doping authority

Unregulated Products Warning: - The MHRA has issued warnings about unregulated "weight loss peptides" sold online, which may be counterfeit, contaminated, or incorrectly dosed. Only obtain prescription medications through NHS services, regulated pharmacies, or CQC-registered clinics

Frequently Asked Questions

Conclusion

The development of GLP-1 receptor agonists and related peptide therapies represents a genuine revolution in weight management medicine. For the first time, pharmacological treatments can produce clinically meaningful and sustained weight loss that approaches — and in some cases rivals — bariatric surgery outcomes.

In the UK, semaglutide (Wegovy®) and liraglutide (Saxenda®) are NICE-approved for weight management, with tirzepatide (Mounjaro®) anticipated to follow. Next-generation agents including retatrutide, survodutide, and CagriSema promise even greater efficacy, though they remain in clinical development.

However, these medications are most effective as part of a comprehensive weight management programme that includes dietary modification, physical activity, behavioural support, and ongoing medical supervision. They are not a substitute for lifestyle changes but rather a tool that makes those changes more achievable by addressing the biological drivers of appetite and metabolism.

Weight management should always be discussed with a qualified healthcare professional who can assess individual suitability, monitor for side effects, and provide appropriate support. The MHRA strongly advises against purchasing unregulated peptide products from online sources.

*This page is for educational and informational purposes only. It is not medical advice. Weight management is a medical concern that should be addressed by qualified healthcare professionals. Consult your GP or a specialist weight management service for personalised guidance.*

Medical Disclaimer

The information provided on this page is for educational and research purposes only. The peptides discussed are not approved medications for the conditions described. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.

Related Categories

GLP-1 Agonists Fat Loss & Metabolic

What this guide is — and what to do first

Standard care first

When to speak to your GP

UK-approved treatments for this condition

What the peptide evidence actually says

How Peptides May Help

Researched Peptides

Semaglutide

Tirzepatide

Liraglutide

Retatrutide

Survodutide

Cagrilintide

AOD-9604

Tesofensine

Peptide Comparisons

Safety Considerations

Frequently Asked Questions

What is the best peptide for weight loss?

Can I get weight loss peptides on the NHS?

How much weight can I lose with peptides?

Are weight loss peptides safe?

What is the difference between Ozempic and Wegovy?

Do I need a prescription for weight loss peptides in the UK?

Conclusion

Medical Disclaimer

Related Categories

Explore Other Guides

Peptides for Tendon Injuries & Repair

Peptides for Fat Loss & Weight Management

Peptides for Muscle Growth & Recovery

Peptides for Anti-Ageing & Longevity

Peptides for Cognitive Enhancement & Brain Health

Immunity Peptides: Peptides for Immune Support & Function

Peptides for Sexual Health & Function

Peptides for Joint Health & Cartilage Repair

Peptides for Sleep Optimization & Sleep Quality

Peptides for Blood Sugar Management & Glycaemic Control

Peptides for Anxiety & Stress Reduction

Peptides for Athletic Performance & Recovery

Peptides for Heart Health & Cardiovascular Support

Peptides for Liver Health & Detoxification

Peptides for Autoimmune Conditions & Immune Modulation

Peptides for Post-Surgery Recovery & Wound Healing

Peptides for Skin Pigmentation & Tanning

Peptides for Fertility & Reproductive Health

Peptides for Diabetes & Blood Sugar Control

Peptides for Bodybuilding & Muscle Gain

Peptides for Knee Pain & Joint Support

Peptides for Back Pain & Spinal Health

Peptides for IBS & Digestive Disorders

Peptides for Depression & Mood Support

Peptides for PCOS (Polycystic Ovary Syndrome)

Peptides for Chronic Fatigue & CFS/ME

Peptides for Neuropathy & Nerve Health

Peptides for Thyroid Health & Function

Peptides for Respiratory & Lung Health

Peptides for Long COVID & Post-Viral Syndrome

Peptides for Fibromyalgia & Chronic Pain

Peptides for Lyme Disease & Post-Treatment Syndrome

Peptides for Erectile Dysfunction & Sexual Performance

Peptides for Infertility: Male & Female Fertility Research

Peptides for Osteoarthritis & Joint Health

Peptides for Menopause: Hot Flashes, Bone Loss, Skin & Mood

Peptides for Migraine Prevention

Peptides for Neuropathic Pain & Nerve Damage

Peptides for Disc Degeneration & Back Pain

Peptides for Frozen Shoulder Recovery

Peptides for Bone Density & Osteoporosis Prevention

Peptides for Cardiovascular Health & Heart Protection

Peptides for Thyroid Function & Support

Musculoskeletal Recovery — peptide research hub

Metabolic and Weight — peptide research hub

Neuro and Mood — peptide research hub

Immune and Inflammation — peptide research hub

Skin and Aesthetics — peptide research hub

Hormonal and Reproductive — peptide research hub

Peptides for Hair Growth & Follicle Health

Peptides for Skin Health & Anti-Ageing

Peptides for Gut Health & Digestive Repair